Breaking News, Collaborations & Alliances

Rokote Partners with Exothera to Bring FINCoVac 2.0 to Clinical Phase I/II Trials

FINCoVac 2.0 represents an intranasal booster for those who are already fully vaccinated with other coronavirus vaccines.

Author Image

By: Charlie Sternberg

Associate Editor

Rokote Laboratories Finland Ltd., a vaccine development company focusing on a second-generation Covid-19 vaccine, has partnered with Exothera S.A. to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials.   Exothera will finetune the industrialization of the FINCOVAC 2.0 process and manufacture clinical material for Phase I/II trials. Bringing FINCoVac 2.0 to Clinical Trials More Quickly FINCoVac 2.0 is designed to address the most critical current coronaviru...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters